Natco Pharma Q2 Results: Net profit and revenue decline from last year; declares dividend

Detailed summary

Natco Pharma has declared a second interim dividend of ₹1.25 per equity share, representing a payout of 62.5% on the face value of ₹2 per share, for FY27. The company has fixed November 19 as the record date to determine shareholders eligible to receive the dividend.

Natco Pharma Ltd. reported a weak set of results for the September quarter of FY27 on Friday, November 13, with revenue, net profit and operating earnings declining sharply on a year-on-year basis.

The pharmaceutical company reported revenue of ₹967.3 crore for Q2FY27, registering a decline of 29% from ₹1,363 crore reported in the corresponding quarter last year.

Net profit for the quarter fell 60.9% year-on-year to ₹202.6 crore, compared with ₹518.4 crore in Q2FY26.

Operating performance also remained under pressure, with Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) declining 55.4% to ₹258 crore from ₹579 crore in the year-ago quarter. EBITDA margin contracted sharply by 1,590 basis points to 26.6% in the September quarter, compared with 42.5% in the corresponding period last year.

Separately, the company's Board of Directors has declared a second interim dividend of ₹1.25 per equity share, representing a payout of 62.5% on the face value of ₹2 per share, for FY27.

The company has fixed November 19, 2026, as the record date to determine shareholders eligible to receive the dividend. The payment process is scheduled to commence from November 27, 2026.

Shares of Natco Pharma Ltd. were trading 0.91% lower at ₹801.45 on Friday. The stock has declined around 10% so far in 2026.

Venky's Q2 results: Poultry company swings to profit, revenue up 33%; shares slump 6%

Gold rebounds after sharp fall, silver lags: What should Indian investors watch

Opening of the article, excerpted from CNBC-TV18. To read the rest, open the article on the publisher's site.